CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤 CAR-T 细胞免疫治疗的下一个创新方向
英文原题：The next innovations in chimeric antigen receptor T cell immunotherapies for cancer.
查看英文原题
The next innovations in chimeric antigen receptor T cell immunotherapies for cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已经改变了癌症治疗和免疫治疗领域。尽管CAR-T 细胞疗法在治疗B细胞恶性肿瘤方面已展现出相当大的临床成功，但将其治疗疗效和可及性扩展到其他血液系统恶性肿瘤和实体瘤仍是一项挑战。关键限制包括生产制造方面的制约以及治疗障碍，如CAR-T 细胞持久性、增殖、肿瘤迁移和治疗相关毒性。为克服与CAR-T 细胞疗法相关的独特挑战，可以利用CAR设计、递送和T细胞功能方面的新技术创新。本综述将探讨三种创新方法：基因编辑和沉默、装甲策略以及体内CAR基因递送。这些方法均旨在提高CAR-T 细胞疗法在血液系统恶性肿瘤中的可及性和治疗疗效。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy has transformed cancer treatment and the field of immunotherapy. Although CAR T cell therapy has demonstrated considerable clinical success for the treatment of B cell malignancies, expanding its therapeutic efficacy and accessibility for other hematological malignancies and solid tumors remains a challenge. Key limitations include manufacturing constraints and therapeutic hurdles, such as CAR T cell persistence, proliferation, tumor trafficking and treatment-related toxicities.
To overcome the unique challenges associated with CAR T cell therapy, novel technological advancements in CAR design, delivery, and T cell functionality can be leveraged. This review will explore three innovative approaches: gene editing and silencing, armoring strategies and in vivo CAR gene delivery. These approaches are all aimed at enhancing the accessibility and therapeutic efficacy of CAR T cell therapy in hematological malignancies.
论文信息
- 作者
- Anupindi K、Malachowski J、Hodson I、Zhu D、June CH、Levine BL
- 第一作者单位
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.United States
- 通讯作者单位
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: levinebl@pennmedicine.upenn.edu.United States
- 文献类型
- 综述
- 期刊
- Cytotherapy2025 Jul
- 原文标识
- PubMed 40542808 · DOI 10.1016/j.jcyt.2025.05.010